Claims for Patent: 8,071,795
✉ Email this page to a colleague
Summary for Patent: 8,071,795
Title: | HIF inhibitors |
Abstract: | HIF-1 inhibitors and methods of use thereof are provided. |
Inventor(s): | Van Meir; Erwin G (Tucker, GA), Nicolaou; Kyriacos (La Jolla, CA) |
Assignee: | Emory University (Atlanta, GA) Scripps Research Institute (LaJolla, CA) |
Application Number: | 11/997,809 |
Patent Claims: | 1. A pharmaceutical composition comprising, a compound selected from one or more of the following: ##STR00001## wherein X is selected from at least one of the following groups:
##STR00002## wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, and R18, are each independently selected from the following groups: H, OH, a branched or unbranched C.sub.1-12 alkyl group, an alkenyl group, an alkoxy
group, an aryl group, a heterocycle group, an imidazole group, a substituted imidazole group, an alkyl substituted aryl group, a halogen substituted an aryl group, a halogen group, an amine group, NO.sub.2, and an acyl group; wherein R19, R20, R21, R22,
R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, and R51 are each independently selected from the following groups: H, OH, a branched or unbranched C.sub.1-12
alkyl group, an alkenyl group, an alkoxy group, an aryl group, a heterocycle group, an imidazole group, a substituted imidazole group, an alkyl substituted aryl group, a halogen substituted aryl group, a halogen group, an amine group, NO.sub.2, and an
acyl group; or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising, one or more compounds selected from the following: ##STR00003## ##STR00004## ##STR00005## wherein R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92, R93, R94, R95, R96, R97, R98, R99, R100, R101, R102, R103, R104, R105, R106, R107, R108, R109, R110, R11, R112, R113, R114, R115, R116, R117, R118, R119, R120, R121, R122, R123, R124, R125, R126, R127, R128, R129, R130, R131, R132, R133, R134, R135, R136, R137, R138, R139, R140, R141, R142, R143, R144, R145, R146, R147, R148, R149, R150, R151, R152, R153, R154, R155, R156, R157, R158, R159, R160, R161, R162, and R163, are each independently selected from the following groups: H, OH, a branched or unbranched C.sub.1-12 alkyl group, an alkenyl group, an alkoxy group, an aryl group, a heterocycle group, an imidazole group, a substituted imidazole group, an alkyl substituted aryl group, a halogen substituted aryl group, a halogen group, an amine group, NO.sub.2, and an acyl group; or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical composition of claim 1, further comprising a second therapeutic compound. 4. The pharmaceutical composition of claim 3, wherein the second therapeutic compound is an antibody, antibiotic, anti-inflammatory, anti-oxidant, analgesic, radioisotope, noscapine, paclitaxel, nocodazole, vinca alkaloids, adriamycin, alkeran, Ara-C, BiCNU, busulfan, CCNU, carboplatinum, cisplatinum, cytoxan, daunorubicin, DTIC, 5-FU, fludarabine, hydrea, idarubicin, ifosfamide, methotrexate, mithramycin, mitomycin, mitoxantrone, nitrogen mustard, velban, vincristine, VP-16, gemcitabine, herceptin, irinotecan, camptosar, CPT-11, leustatin, navelbine, rituxan, STI-571, taxotere, temozolomide, topotecan, hycamtin, xeloda, capecitabine, zevelin, and combinations thereof. 5. The pharmaceutical composition of claim 2, further comprising a second therapeutic compound. 6. The pharmaceutical composition of claim 5, wherein the second therapeutic compound is an antibody, antibiotic, anti-inflammatory, anti-oxidant, analgesic, radioisotope, noscapine, paclitaxel, nocodazole, vinca alkaloids, adriamycin, alkeran, Ara-C, BiCNU, busulfan, CCNU, carboplatinum, cisplatinum, cytoxan, daunorubicin, DTIC, 5-FU, fludarabine, hydrea, idarubicin, ifosfamide, methotrexate, mithramycin, mitomycin, mitoxantrone, nitrogen mustard, velban, vincristine, VP-16, gemcitabine, herceptin, irinotecan, camptosar, CPT-11, leustatin, navelbine, rituxan, STI-571, taxotere, temozolomide, topotecan, hycamtin, xeloda, capecitabine, zevelin, and combinations thereof. 7. A method of modulating HIF activity in a cell comprising: contacting the cell with a HIF inhibiting amount of the compositions of claim 2. 8. A method of treating cancer or a tumor in a host comprising administering to the host a HIF inhibiting amount of the compositions of claim 2 wherein the cancer or tumor is selected from the group consisting of cervical, ovarian, colon, breast, gastric, lung, skin, ovarian, pancreatic, prostate, and renal cancer. 9. A pharmaceutical composition of claim 1, wherein the compound of Formula B is N-cyclohexyl-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-2,4-dimethoxybenzen- esulfonamide or salt thereof. 10. A pharmaceutical composition of claim 1, wherein the compound of Formula C is N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-isobutyl-3,4-dimethoxybenzenes- ulfonamide or salt thereof. 11. A pharmaceutical composition of claim 1, wherein the compound of Formula D is N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-3,4-dimethoxy-N-phenylbenzenesul- fonamide or salt thereof. |
Details for Patent 8,071,795
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2025-08-25 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2025-08-25 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2025-08-25 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.